Review of the Clinical Effect of Orlistat
Author:
- Xiguang QiXQXiguang Qi
Open Access
- 1 January 2018
- conference paper
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 301 (1) , 012063
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Long term pharmacotherapy for obesity and overweight: updated meta-analysisBMJ, 2007
- Drugs in the treatment of obesity: sibutramine, orlistat and rimonabantPublic Health Nutrition, 2007
- Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosageExpert Opinion on Pharmacotherapy, 2007
- Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor CellsCancer Research, 2007
- Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitorThe FASEB Journal, 2006
- OrlistatDrugs, 2006
- Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogeneAnnals of Oncology, 2005
- OrlistatDrugs, 2004
- Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid)International Journal of Obesity, 2001
- Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988